Dr Reddy's Labs surges 8% on approval for generic Suboxone Film launch

The stock surged 8% to Rs 2,652 on the BSE in early morning trade, quoting near to its 52-week high of Rs 2,687 touched on September 28, 2018 in intra-day deal.

Shares of Dr Reddy’s Laboratories have surged  8% to Rs 2,652 on the BSE (52-week high of Rs 2,687) after the US Court of Appeals lifted a temporary ban on the company’s generic Suboxone film.

The drug, reports suggest, is used to treat opioid use disorder. 

“The United States Court of Appeals for the Federal Circuit issued a decision in favor of Dr. Reddy's Laboratories Inc., concluding that lndivior had not shown that it is likely to succeed on the merits of its infringement case on U.S. Patent No. 9,931,305,” Dr Reddy’s Laboratories said in a release.